We are live on ! Find out more
OPRX icon

OptimizeRx

97 hedge funds and large institutions have $155M invested in OptimizeRx in 2024 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 24 increasing their positions, 38 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,662% more call options, than puts

Call options by funds: $229K | Put options by funds: $13K

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

1.16% more ownership

Funds ownership: 69.26%70.42% (+1.2%)

6% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 17

1% less funds holding

Funds holding: 9897 (-1)

14% less capital invested

Capital invested by funds: $180M → $155M (-$24.5M)

37% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 38

Holders
97
Holders Change
-1
Holders Change %
-1.02%
% of All Funds
1.4%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
16
Increased
24
Reduced
38
Closed
17
Calls
$229K
Puts
$13K
Net Calls
+$216K
Net Calls Change
-$3.16M
Name Holding Trade Value Shares
Change
Change in
Stake
FLAM
1
First Light Asset Management
Minnesota
$21.1M +$149K +10,286 +0.6%
DSCM
2
Divisadero Street Capital Management
Florida
$19.1M +$9.04M +623,350 +66%
BlackRock
3
BlackRock
New York
$13.2M -$720K -49,678 -4%
Vanguard Group
4
Vanguard Group
Pennsylvania
$12.5M +$91.2K +6,291 +0.6%
AIC
5
AWM Investment Company
New York
$10.4M +$479K +33,000 +4%
William Blair & Company
6
William Blair & Company
Illinois
$9.51M +$601K +41,469 +6%
SM
7
Samjo Management
New York
$6.87M +$2.24M +154,543 +38%
RHJA
8
Rice Hall James & Associates
California
$4.88M +$858K +59,141 +17%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$4.69M +$106K +7,325 +2%
GIPM
10
G2 Investment Partners Management
New York
$4.53M -$1.38M -95,086 -20%
D.E. Shaw & Co
11
D.E. Shaw & Co
New York
$4.24M -$1.65M -113,615 -25%
State Street
12
State Street
Massachusetts
$4.07M +$207K +14,280 +4%
KCM
13
Kennedy Capital Management
Missouri
$3.89M -$2.48M -170,886 -35%
CS
14
Credit Suisse
Switzerland
$3.82M -$45K -3,103 -1%
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$3.5M +$460K +31,742 +12%
Federated Hermes
16
Federated Hermes
Pennsylvania
$2.25M +$30.2K +2,085 +1%
Northern Trust
17
Northern Trust
Illinois
$1.86M -$77.8K -5,362 -3%
JP Morgan Chase
18
JP Morgan Chase
New York
$1.69M +$176K +12,152 +10%
BAM
19
Bullseye Asset Management
Colorado
$1.49M
BCM
20
Bridgeway Capital Management
Texas
$1.35M -$199K -13,700 -11%
PCM
21
Perkins Capital Management
Minnesota
$1.28M
Bank of New York Mellon
22
Bank of New York Mellon
New York
$1.24M -$67.1K -4,630 -4%
BFM
23
Boothbay Fund Management
New York
$1.1M -$504K -34,751 -28%
AC
24
Avenir Corporation
Virginia
$1.07M
EIM
25
Essex Investment Management
Massachusetts
$1.05M +$1.26M +86,656 New

OPRX Hedge Fund Activity: Q1 2024 in Review

97 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in OptimizeRx (OPRX) for Q1 2024, worth a combined $155M — down 14% from $180M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of OPRX and 16 opened new positions — a net loss of 1 holder — while 38 trimmed existing stakes and 24 added.

The largest buyer was Divisadero Street Capital Management, adding an estimated $9.04M. The largest seller was Kennedy Capital Management, cutting an estimated $2.48M.

  • 97 institutional investors held OptimizeRx (OPRX) as of Q1 2024, down from 98 in Q4 2023.
  • Funds reported $155M of OptimizeRx stock for Q1 2024, down 14% quarter-over-quarter.
  • 16 funds opened new OptimizeRx positions in Q1 2024 and 17 closed out, a net change of -1 holder.
  • The largest OptimizeRx buyer in Q1 2024 was Divisadero Street Capital Management, an estimated $9.04M added.
  • The largest OptimizeRx seller in Q1 2024 was Kennedy Capital Management, an estimated $2.48M sold.

Based on aggregated 13F filings for Q1 2024.